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Background: Nobori is a new generation drug eluting stent, coated only abluminally with a biodegradable polymer and Biolimus A9. Bifurcation 
lesions represent a particular challenge for PCI treatment, with in general inferior results compared to non-bifurcated lesions, despite use of various 
treatment strategies.
Methods: The NOBORI 2 is a large multicentre registry of consecutive patients treated with Nobori stent. The primary endpoint is the composite of 
cardiac death, MI and TLR at 1 year. Among the first 1000 patients treated in this study 175 had at least one bifurcation and those patients were 
compared with patients without bifurcation. All adverse events are adjudicated by independent event committee.
Results: Baseline demographic characteristics were comparable between both groups, except for male gender which was more represented in 
bifurcation group (88% vs. 80%, p=0.003). Number of lesions treated (1.73 vs. 1.39, p<0.0001), and number of stents implanted per patient (2.06 
vs. 1.65, p=0.0012) were significantly higher in the bifurcation group, with more frequent compromised sidebranch in the bifurcation group (5.9% 
vs. 1.3%, p<0.0001). Lesions in the bifurcation subgroup were more complex (type B2/C 91.7% vs. 67.5%, p<0.001) and more frequently located 
in the left coronary system (84.0% vs. 64.6%, p<0.001). There was no significant difference between groups for both pre- and post-procedure RVD, 
MLD and % diameter stenosis at baseline. MACE rate was low in both groups up to 6 months (4.3% vs. 3.7% in bifurcation and non-bifurcation group 
respectively). Stent thrombosis rate was 0.7% and did not differ significantly between the groups. One year follow-up is ongoing and results will be 
avilable at the time of presentation.
Conclusions: Preliminary 6 months results of patients treated with Nobori stent in bifurcation and non-bifurcation subsets are very encouraging. 
Low rates of death, MI, TLR and stent thrombosis were observed, despite very complex lesion characteristics.
